
Customize View
Recently disclosed strategic alliances only (within the last two years)
Include Strategic Alliances for:Current subsidiaries



Strategic Alliances

Recently Disclosed Strategic Alliances
Strategic Alliance Name
Company Name
Primary Industry
Source
Antares Pharma, Inc.
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Pharmaceuticals
Antares Pharma, Inc. 2021 Form 10-K
Business Description: Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company’s injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey. As of May 23, 2022, Antares Pharma, Inc. operates as a subsidiary of Halozyme Therapeutics, Inc.
Astellas Pharma Inc. (TSE:4503)
Teva Takeda Pharma Ltd.
Pharmaceuticals
Astellas Pharma Inc. (TSE:4503) - Form Doc
Business Description: Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. The company was founded in 1923 and is headquartered in Tokyo, Japan.
Astellas Pharma Inc. (TSE:4503)
Teva Takeda Pharma Ltd.
Pharmaceuticals
Astellas Pharma Inc. (TSE:4503) - Form Doc
Business Description: Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. The company was founded in 1923 and is headquartered in Tokyo, Japan.
Celltrion, Inc. (KOSE:A068270)
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Biotechnology
Celltrion, Inc. (KOSE:A068270) - Form 
Business Description: Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 3 clinical trial; CT-P17 for the treatment of autoimmune diseases which is in phase 3 clinical trial; CT-P16 for the treatment of non-small cell lung cancer and colon cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 3 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P47 for the treatment of rheumatoid arthritis, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial. The company was founded in 2002 and is headquartered in Incheon, South Korea.
Cipla Limited (NSEI:CIPLA)
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Pharmaceuticals
Cipla Limited (NSEI:CIPLA) - Form Doc
Business Description: Cipla Limited, together with its subsidiaries, manufactures, develops, and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New ventures segments. It also offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women’s health, ophthalmology, and neuro psychiatry. In addition, the company provides respiratory products, including inhalers and nasal sprays, as well as other respiratory products consists of injectables and biosimilars. Further, it offers Easylax and Easylax L, a liquid paraffin for constipation. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.
Evotec SE (XTRA:EVT)
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Life Sciences Tools and Services
Evotec SE (XTRA:EVT) - Form 
Business Description: Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women’s health. It has collaboration agreements with Bayer; Lilly; Almirall; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Janseen Biotech; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Galena Biopharma, Inc. (Acquired)
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Biotechnology
Galena Biopharma, Inc. 2016 Form 10-K
Business Description: As of December 29, 2017, Galena Biopharma, Inc. was acquired by SELLAS Life Sciences Group AG, in a reverse merger transaction. Galena Biopharma, Inc., a biopharmaceutical company, develops hematology and oncology therapeutics that address unmet medical needs. The company develops GALE-401 (anagrelide controlled release), which completed Phase II clinical trial for the treatment of patients with myeloproliferative neoplasms to lower elevated platelet levels. It also develops NeuVax (nelipepimut-S), which is in Phase IIb clinical trial in combination with trastuzumab for HER2 1+ and 2+ node positive and high-risk node negative breast cancer patients; Phase II clinical trial in combination with trastuzumab for HER2 3+ breast cancer patients; Phase II clinical trial for women with ductal carcinoma in situ of the breast; and Phase II clinical trial for patients with gastric cancer. In addition, the company develops GALE-301 and GALE-302 for ovarian, endometrial, and breast cancers. It has strategic development and commercialization partnership with Dr. Reddy’s Laboratories Ltd. for NeuVax in breast and gastric cancers. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Galena Biopharma, Inc. in September 2011. Galena Biopharma, Inc. was founded in 2003 and is based in San Ramon, California.
Hyundai Pharmaceutical Co., Ltd. (KOSE:A004310)
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Pharmaceuticals
Hyundai Pharmaceutical Co., Ltd. (KOSE:A004310) - Form 
Business Description: Hyundai Pharmaceutical Co., Ltd. manufactures and distributes pharmaceutical products, health food drinks, and medical equipment in South Korea and internationally. The company offers a range of ETC and OTC products in various therapeutic areas, including antianginal, antibiotic, antiemetics+antinauseants, antihistamines and antiallergics, antihyperlipidemic, antihypertensive, antiplatelet agent, antitussives, cell stimulants and proliferants, central nervous system, depilatory, dermatological agent, dermatology, dietary supplements, digestive system, endocrine system, expectorants, eye tonic and eye vitamins, gynaecolog antifungals, gynaecologic antiseptics, hemostatics, labour inhibitors, leukotriene modulator, narcotic analgesics, NSAIDs, oestrogens, ophthalmic products, OTH.sex horm and similar, SERMS, systemic hormonal contraceptives, urogenital system depilatory, uterotonic products, various alimentary tract and metabolism products, vitamins, acne, allergy, alopecia treatment, analgesics and anti-inflammatory, anemia, antimicrobial and antivirus, arthritis, contraceptives, dermatological agent, diagnostic reagent, gastrointestinal disorder and digestant, lip care, nutrition, ophthalmic product, respiratory, urogenital system, wound healing, and others. The company was founded in 1965 and is headquartered in Seoul, South Korea.
Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276)
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Pharmaceuticals
Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276) - Form 
Business Description: Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, develops, manufactures, and commercializes drugs worldwide. The company is developing Camrelizumab, Pyrotinib, Fuzuloparib, Adebrelimab, Rezvilutamide, Famitinib, Dalpiciclib, SHR-1701, SHR-1501, SHR-A1811, SHR1459, Mecapegfilgrastim, Apatinib, Linperlisib, and SHR2554 for oncology indications; SHR4640, Retagliptin, SHR20004, SHR-1209, SHR3824, INS068, SHR7280, and SHR2285 for cardiovascular and metabolism indications. It is also developing SHR0302, Hetrombopag, Vunakizumab, and SHR-1703 for autoimmune indications; SHR0410, Imrecoxib, Remimazolam, and SHR8554 for pain; Oteseconazole and HRS9950 for anti-infection; and SHR8028, SHR8058, SHR-1707, and SHR-1222 for other indications. The company was founded in 1970 and is based in Lianyungang, China.
Just - Evotec Biologics, Inc.
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Biotechnology
Key DevelopmentClient Announcements Jun-28-2019
Business Description: Just - Evotec Biologics, Inc. develops protein therapeutics. It also engages in molecular design, process design, and plant design services. The company offers services related to protein, process, and manufacturing sciences; and focuses on the technology of biotherapeutics. Its products include J.DESIGN, an integrated technology platform for biotherapeutic development. The company was incorporated in 2014 and is based in Seattle, Washington with additional office in Redmond, Washington; Hamburg, Germany; and Toulouse, France. Just - Evotec Biologics, Inc. operates as a subsidiary of Evotec SE.
JW Holdings Corporation (KOSE:A096760)
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Pharmaceuticals
JW Holdings Corporation (KOSE:A096760) - Form 
Business Description: JW Holdings Corporation, together with its subsidiaries, manufactures and sells medicines and medical devices in South Korea and internationally. It offers ETC products, consumer healthcare OTC products, and IV solutions machinery systems. The company also exports its products. JW Holdings Corporation was founded in 1945 and is based in Seoul, South Korea.
Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND)
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Pharmaceuticals
Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) 2019 Form 10-K
Business Description: Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in San Diego, California.
Medical Union Pharmaceuticals Company
Mepha Holding AG
Pharmaceuticals
Medical Union Pharmaceuticals Company - Form 
Business Description: Medical Union Pharmaceuticals Company develops, manufactures, and distributes generic and pharmaceutical products in Egypt. The company offers products that cover various therapeutic areas, including gastroenterology, dermatology, gynecology, andrology, cardiovascular, dentistry, anti-infectives, anti-histaminics, analgesics and anti-rheumatics, endocrinology, hepatology, respiratory, and neurology, as well as vitamins and tonic products. It also exports its products to approximately 30 countries. Medical Union Pharmaceuticals Company is headquartered in Cairo, Egypt.
MINAPHARM Pharmaceuticals (CASE:MIPH)
Actavis Pharma, Inc.
Pharmaceuticals
MINAPHARM Pharmaceuticals (CASE:MIPH) - Form 
Business Description: MINAPHARM Pharmaceuticals operates as a pharmaceutical company primarily in Egypt and the Middle East. The company’s products include Angiofox capsules, Artelac and Berberil eye drops; Bon-one, Ciprodiazole, Dumozol, Hydroquine, and Burinex tablets; Chlorhexidine; DICYNONE; Corneregel fluid and ophthalmic gel; Betolvex and Fleboton ampoules; Deponit patches; Dexagel viscous eye drops; Doxiproct plus and Doxiproct ointment; Doxium capules; Broncho-Vaxom capsules for adults and infants; Broncho-Vaxom infant sachets; Netophtiole plus eye drops; Extrauma cream; and Ophtatrov and Optatrov plus. It also provides Ferroduonal, Lipanthyl, Parafon, Ribavirin, Uro-Vaxom, Ursofalk, Ursoplus, Ursotwin, and Ferro Sanol Gyn capsules; Gyno-Pevaryl, Pevisone, Srilane, and Pevaryl cream; Gonapure; Hair Plus Back 2% and 5%; Hair Plus Back Topical FOAM; Lucidril 500; Lucidril, Salofalk, Trimed flu, XerovirinC, Pixcolt, and Ossopan tablets; Thrombexx ampoules, cream, and gel; Vidisept N drops; and Luciforte, Oxytocin, Reiferon Retard, and Nausilex ampoules. The company offers its products for the treatment of hematoma and thrombosis, iron deficiency anemia, recurrent urinarytract infections, immunostimulants, osteoporosis, renal osteodystrophy, loop diuretics, prophylaxis, hemorrhoids, rheumatoid arthritis, hyperlipidemia, alopecia, skin infections, topical corticosteroids, gynecological antifungals, vaginal infections, anti-infective, dyslipidemia, muscle spasm, dry eye, eye inflammation and allergy, corneal, nausea and vomiting, hepatology and gastroenterology, coronary heart, respiratory tract infections, occular irritation, labour induction, cerebral insufficiency, surgical dressing, prophylaxis, pregnancy and lactation, hemostasis, hemorrhage, infertility, and microvascular diseases, as well as vitamin B12 deficiency, anemia, and diabetic neuropathy. The company was founded in 1958 and is headquartered in Cairo, Egypt.
Otsuka Pharmaceutical Co., Ltd.
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Pharmaceuticals
Teva Pharmaceutical Industries Limited (NYSE:TEVA) 2023 Form 10-K
Business Description: Otsuka Pharmaceutical Co., Ltd. engages in pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products, such as Rexulti (brexpiprazole) for the treatment of schizophrenia in adults; and Abilify Maintena (aripiprazole), a once-monthly injectable formulation for intramuscular use for the maintenance monotherapy treatment of bipolar I disorder (BP I) in adults; Neupro patch; Selinco; Iclusig; and Pletaal; and otc drugs, such as Oronine and New Saralin. Otsuka Pharmaceutical Co., Ltd. offers drugs for central nervous system, tuberculosis, ophthalmology, and oncology diseases. It also provides EQUELLE, a product for women's health and beauty; BODYMAINTÉ Jelly, a conditioning food product; BODYMAINTÉ Drink, a drinkable-liquid; POCARI SWEAT, a drink; Calorie Mate, a nutritional food; SOYJOY, a soy bar; and REHADAYS, a beverage to support exercise and rehabilitation. In addition, the company offers soft drinks, clinical testing, medical equipment, and cosmetics. The company was founded in 1964 and is based in Tokyo, Japan with branch and district offices in Japan. Otsuka Pharmaceutical Co., Ltd. operates as a subsidiary of Otsuka Holdings Co., Ltd.
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER)
Watson Laboratories, Inc.
Pharmaceuticals
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) 2013 Form 
Business Description: Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. researches, develops, manufactures, markets, and sells pharmaceutical products worldwide. The company operates through two segments, Pharmaceuticals, and Wholesale and Retail. It develops and manufactures products in various therapeutic areas, including women’s healthcare, cardiovascular, and central nervous system. The company offers women’s healthcare products for contraceptives, endometriosis, fertility, menopause, vaginal infections, and uterine fibroids. It also provides central nervous system products, such as products for the treatment of chronic cerebral circulatory disorders and neuropathic pain; and aesthetics, anti-anxiety medications, sleeping pills, and anti-epileptic medicines, as well as products for the prevention and treatment of various cardiovascular diseases. In addition, the company produces various over-the-counter products for various health problems comprising Panangin for heart support; Escapelle and Postinor, an emergency contraceptive pill; Stopdiar and Nifuroxazide to treat diarrhea; RICHTER CycleBalance for infertility and PCOS; Curiosin for wound care; Groprinosin for antiviral and immunostimulant; Folik, a pregnancy supplement; Moilec for back and joint pain; Fasconal, a pain relief tablet; Lordestin for allergy; Magnezin, a magnesium supplement; Aflamil, an anti-inflammatory and antirheumatic cream; Oralsept, a sore throat and local anesthetic. Further, it provides financial and accounting, social and welfare, portfolio and project management, catering, carriage transportation, engineering, quality control, trading, asset management, and biotechnological services. Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. was founded in 1901 and is headquartered in Budapest, Hungary.
Rimidi, Inc.
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Health Care Technology
Key DevelopmentClient Announcements Nov-14-2022
Business Description: Rimidi, Inc. develops cloud-based clinical management solutions for the management of chronic conditions like diabetes, heart failure, and cardiovascular disease. The company's solutions include rimidi Orthopedics, a mobile app for surgeons integrated with the EMR, a patient-facing mobile app for outcomes tracking and outcomes reporting; DBS CareTrek, a patient journey app for neurologic conditions; Rimidi’s Epidemic Monitoring Platform, a solution for hospitals, health systems, employers, and universities to triaging and monitoring their populations. In addition, it offers chronic condition management solutions for diabetes, heart failure, fatty liver disease, cardiovascular disease, and obesity. The company serves health care providers, community health-focused organizations, and payers. Rimidi Inc. was formerly known as Rimidi Diabetes, Inc. and changed its name to Rimidi Inc. in July 2018. The company was incorporated in 2012 and is based in Atlanta, Georgia.
Samil Pharmaceutical Co.,Ltd (KOSE:A000520)
Teva Italia Srl
Pharmaceuticals
Samil Pharmaceutical Co.,Ltd (KOSE:A000520) - Form 
Business Description: Samil Pharmaceutical Co.,Ltd engages in the manufacture and sale of indispensable medicines in South Korea. It offers hepatic, gastrointestinal, vasodilator, antithrombotic, respiratory, skeletal muscle relaxants, circulatory, neurological, antibiotics, metabolic, antihistamines, immunosuppressive, hormone, anti-tumor, urinary, and ophthalmic drugs, as well as antipyretic, analgesic, and anti-inflammatory agents. The company also provides OTC products and sanitary aids. Samil Pharmaceutical Co.,Ltd was founded in 1947 and is headquartered in Seoul, South Korea.
Takeda Pharmaceutical Company Limited (TSE:4502)
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Pharmaceuticals
Teva Pharmaceutical Industries Limited (NYSE:TEVA) 2023 Form 10-K
Business Description: Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, JCR Pharmaceuticals, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.
xCella Biosciences Inc.
Teva Pharmaceuticals Australia Pty Ltd
Biotechnology
Key DevelopmentClient Announcements Apr-09-2019
Business Description: xCella Biosciences Inc. develops therapeutics using protein engineering and disruptive technology. The company was incorporated in 2015 and is based in Menlo Park, California. As of September 8, 2020, xCella Biosciences Inc. operates as a subsidiary of Ligand Pharmaceuticals Incorporated.
*denotes proprietary relationship